Kolon TissueGene (XKRX:950160) ROCE % : -50.35% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Kolon TissueGene ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kolon TissueGene's annualized ROCE % for the quarter that ended in Dec. 2024 was -50.35%.

Kolon TissueGene ROCE % Historical Data

The historical data trend for Kolon TissueGene's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon TissueGene ROCE % Chart

Kolon TissueGene Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-49.00

-90.74

-13.17

-15.25

-24.88

Kolon TissueGene Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-12.32	-12.39	-14.84	-13.38	-50.35

Kolon TissueGene ROCE % Calculation

Kolon TissueGene's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-33804.437	/	( ( (134910.381 - 14303.353)	+	(222288.124 - 71110.719) )	/ 2 )
	=	-33804.437	/	( (120607.028	+	151177.405)	/ 2 )
	=	-33804.437	/	135892.2165
	=	-24.88 %

Kolon TissueGene's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-76786.092	/	( ( (192872.644 - 39022.218)	+	(222288.124 - 71110.719) )	/ 2 )
	=	-76786.092	/	( ( 153850.426	+	151177.405 )	/ 2 )
	=	-76786.092	/	152513.9155
	=	-50.35 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Kolon TissueGene (XKRX:950160) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kolon TissueGene ROCE % Related Terms

Thank you for viewing the detailed overview of Kolon TissueGene's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kolon TissueGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kolon TissueGene Inc (XKRX:950160) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

9713 Key West Avenue, Suite 300, Rockville, MD, USA, 20850

Website

https://www.tissuegene.com

Kolon TissueGene Inc is a biopharmaceutical company that develops regenerative therapies for the treatment of various orthopedic disorders. It is developing four product candidates, TG-C, TG-B, TG-D and TG-N for regeneration of cartilage, bone, disc and nerve.

Kolon TissueGene Headlines

No Headlines